CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Eletriptan hydrobromide

Last Updated: September 21, 2004
Result type: Reports
Project Number: SR0021-000
Product Line: Reimbursement Review

Generic Name: Eletriptan hydrobromide

Brand Name: Relpax

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Migraine

Indications: Migraine

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 23, 2005

Recommendation Type: Do not list